Latest News
Candel Therapeutics, Inc.
- Candel Welcomes New General Counsel
- Candel Therapeutics Appoints Maria Ostrovsky General Counsel Ahead of Planned FDA Submission
- A legal executive with 20 years' experience will join Candel as it plans to seek approval for a prostate cancer treatment.
- Candel Therapeutics Appoints Maria Ostrovsky as General Counsel
- Candel Therapeutics initiated with a Buy at Jefferies
- Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data
- Analysts Expect Breakeven For Candel Therapeutics, Inc. (NASDAQ:CADL) Before Long
- Form 4 Candel Therapeutics Inc: Paul B. Manning (Director) For: 30 September
- Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Candel Therapeutics releases new digital pathology data supporting aglatimagene immune activation in prostate cancer
- Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Headlines from the last 30 days, linking to the original publishers. See all market news →